Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 203articles · 30d
- 9+ hour agolatest article
- Aug 16, 2026earliest in window
- 95%with images
- 246avg words
- Medical 150
- Health & Wellness 138
- Health 100
- Science & Technology 46
- Business & Industrial 37
- Economy, Business & Finance 22
- Politics 19
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why two promising heart drugs flopped and what's next
3+ day, 14+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did…...
Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
3+ day, 21+ hour ago (208+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the…...
Orexin discoverers awarded prestigious Lasker award
4+ day, 18+ hour ago (160+ words) By Elaine Chen and Allison DeAngelis First came the new teaser for Nathan Fielder’s documentary on Elizabeth Holmes. Now come the memes. Bring it on. For the past few months, key centers at the FDA have been led by acting…...
AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies
5+ day, 20+ hour ago (187+ words) STAT AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies Approval could deliver patients a new options and produce a windfall for the pharma company Andrew covers the biopharma industry, scientific research, and public health across the continent. You…...
Inhibrx claims first win for long-sought immunotherapy target
5+ day, 20+ hour ago (136+ words) statnews.com Inhibrx said Tuesday that its experimental immunotherapy targeting a protein called OX40 showed responses in patients with head and neck cancer. But the most striking results were in a small subset of patients with HPV-positive tumors, which could significantly…...
Roivant lung disease drug hits mid-stage study goals
5+ day, 22+ hour ago (242+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the…...
Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
6+ day, 21+ hour ago (130+ words) STAT Novo Nordisk has stopped two trials of a drug that aims to tame inflammation as a way to improve cardiovascular health, another blow for the approach. The company said it had halted the HERMES and ATHENA trials of its…...
After failure of Angelman syndrome drug, experts see hope in other experimental therapies
1+ week, 2+ day ago (205+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
We're reading about an Ultragenyx failure, RevMed for lung cancer, and more
1+ week, 3+ day ago (252+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
Abivax has still not been acquired. What’s going on?
1+ week, 3+ day ago (225+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the…...